Patents by Inventor Masatora Fukuda

Masatora Fukuda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240093227
    Abstract: Provided is an oligonucleotide which may induce an editing activity of ADRC in cell and has excellent stability in a living body. The oligonucleotide includes a first oligonucleotide identifying a target RNA and a second oligonucleotide linked to the 5?-side of the first oligonucleotide. The first oligonucleotide consists of a target-corresponding nucleotide residue, an oligonucleotide of 10 to 24 residues at the 3?-side, and an oligonucleotide of 3 to 6 residues at the 5?-side. The second oligonucleotide has no nucleotide residue corresponding to a nucleotide residue of the target RNA or has a nucleotide residue which does not form a complementary pair at the 3?-end thereof and the number of residue is 3 to 6.
    Type: Application
    Filed: December 8, 2021
    Publication date: March 21, 2024
    Applicants: FUKUOKA UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Masatora FUKUDA, Makoto KOIZUMI, Shinzo IWASHITA
  • Publication number: 20230265431
    Abstract: Provided is a short-chain guide RNA that is able to induce site-specific editing even when only a small number of nucleotides is attached to the target recognition site. The guide RNA includes a first oligonucleotide that identifies the target RNA, and a second oligonucleotide that links to the 3? end of the first oligonucleotide. The first oligonucleotide contains: a target-corresponding nucleotide residue that corresponds to an adenosine residue in the target RNA; an oligonucleotide of 15 to 30 residues that links to the 5? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA; and an oligonucleotide of 3 or 4 residues that links to the 3? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA. The second oligonucleotide contains 2 to 24 nucleotide residues, and induces site-specific editing of the target RNA.
    Type: Application
    Filed: March 22, 2023
    Publication date: August 24, 2023
    Applicants: FUKUOKA UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Masatora FUKUDA
  • Patent number: 11643658
    Abstract: Provided is a short-chain guide RNA that is able to induce site-specific editing even when only a small number of nucleotides is attached to the target recognition site. The guide RNA includes a first oligonucleotide that identifies the target RNA, and a second oligonucleotide that links to the 3? end of the first oligonucleotide. The first oligonucleotide contains: a target-corresponding nucleotide residue that corresponds to an adenosine residue in the target RNA; an oligonucleotide of 15 to 30 residues that links to the 5? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA; and an oligonucleotide of 3 or 4 residues that links to the 3? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA. The second oligonucleotide contains 2 to 24 nucleotide residues, and induces site-specific editing of the target RNA.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: May 9, 2023
    Assignees: FUKUOKA UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Masatora Fukuda
  • Publication number: 20230061732
    Abstract: An oligonucleotide that induces a site-specific editing for a target RNA, the oligonucleotide including a first oligonucleotide that specifies the target RNA, a second oligonucleotide that is linked to the 3?-side of the first oligonucleotide, a third oligonucleotide that is capable of forming a complementary pair together with the second oligonucleotide, and a first linking portion that links the second oligonucleotide and the third oligonucleotide. The first oligonucleotide is composed of a target-corresponding nucleotide residue that corresponds to an adenosine residue in the target RNA; an oligonucleotide of 10 to 30 residues linked to the 5?-side of the target-corresponding nucleotide residue and having a base sequence complementary to the target RNA; and an oligonucleotide of 3-6 residues linked to the 3?-side of the target-corresponding nucleotide residue and having a base sequence complementary to the target RNA.
    Type: Application
    Filed: June 4, 2020
    Publication date: March 2, 2023
    Applicants: FUKUOKA UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Masatora FUKUDA, Makoto KOIZUMI, Shinzo IWASHITA
  • Publication number: 20220325281
    Abstract: An oligonucleotide that can induce editing activity specific to adenosine deaminase-1. The oligonucleotide includes a first oligonucleotide for identifying a target RNA and a second oligonucleotide linked to the 5? side of the first oligonucleotide, and that induces site-specific editing of the target RNA. The first oligonucleotide includes a target-corresponding nucleotide residue that corresponds to an adenosine residue in the target RNA; an oligonucleotide comprising 10-24 residues that is linked to the 3? side of the target-corresponding nucleotide residue and has a base sequence which is complementary to the target RNA; and an oligonucleotide comprising 3-6 residues that is linked to the 5? side of the target-corresponding nucleotide residue and has a base sequence which is complementary to the target RNA.
    Type: Application
    Filed: September 25, 2020
    Publication date: October 13, 2022
    Inventor: Masatora FUKUDA
  • Publication number: 20220275359
    Abstract: [Problem to be Solved] To provide a guide RNA. [Solution] A guide RNA for editing a target RNA sequence, comprising an antisense nucleotide sequence complementary to a portion of the target RNA sequence, a short-chain ADAR-recruiting nucleotide sequence, and at least one functional nucleotide sequence.
    Type: Application
    Filed: July 31, 2020
    Publication date: September 1, 2022
    Applicants: Astellas Pharma Inc., Fukuoka University
    Inventors: Eiji YOSHIMI, Yukari MORIYA, Mariko MANDA, Masatora FUKUDA
  • Patent number: 11390865
    Abstract: A method for inducing a site-directed RNA mutation is provided. The method includes repairing an RNA mutation by converting target adenosine, which is located at a target editing site of a target RNA, into inosine. The method for inducing a site-directed RNA mutation involves reacting the target RNA having a target adenosine with a target editing guide, which has been constructed so as to form a complementary strand with target RNA, to form a double-stranded complex, and converting the target adenosine to inosine by causing ADAR to act on the double-stranded complex, inducing A-to-I editing capability. The converted inosine is further translated into guanosine.
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: July 19, 2022
    Assignee: FUKUOKA UNIVERSITY
    Inventors: Masatora Fukuda, Hiromitsu Umeno
  • Publication number: 20200392496
    Abstract: Provided is a short-chain guide RNA that is able to induce site-specific editing even when only a small number of nucleotides is attached to the target recognition site. The guide RNA includes a first oligonucleotide that identifies the target RNA, and a second oligonucleotide that links to the 3? end of the first oligonucleotide. The first oligonucleotide contains: a target-corresponding nucleotide residue that corresponds to an adenosine residue in the target RNA; an oligonucleotide of 15 to 30 residues that links to the 5? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA; and an oligonucleotide of 3 or 4 residues that links to the 3? end of the target-corresponding nucleotide residue and that has a base sequence complementary to the target RNA. The second oligonucleotide contains 2 to 24 nucleotide residues, and induces site-specific editing of the target RNA.
    Type: Application
    Filed: December 5, 2018
    Publication date: December 17, 2020
    Applicants: FUKUOKA UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Masatora FUKUDA
  • Publication number: 20180208924
    Abstract: A method for inducing a site-directed RNA mutation is provided. The method includes repairing an RNA mutation by converting target adenosine, which is located at a target editing site of a target RNA, into inosine. The method for inducing a site-directed RNA mutation involves reacting the target RNA having a target adenosine with a target editing guide, which has been constructed so as to form a complementary strand with target RNA, to form a double-stranded complex, and converting the target adenosine to inosine by causing ADAR to act on the double-stranded complex, inducing A-to-I editing capability. The converted inosine is further translated into guanosine.
    Type: Application
    Filed: July 14, 2016
    Publication date: July 26, 2018
    Inventors: Masatora FUKUDA, Hiromitsu UMENO
  • Patent number: 9238814
    Abstract: The hammerhead ribozyme according to the present invention produces a hammerhead ribozyme—target RNA construct by base-pairing with an edited target RNA, and an editing recognition site of the hammerhead ribozyme cleaves the modification site by forming a base pair with the target RNA modification site. The cleavage of the modification site is expected to be applicable to the research and development of new drugs that can be used to prevent or treat diseases caused by the edited target RNA.
    Type: Grant
    Filed: May 19, 2012
    Date of Patent: January 19, 2016
    Assignee: Fukuoka University
    Inventors: Masatora Fukuda, Masanobu Deshimaru, Kei Kurihara
  • Publication number: 20140228556
    Abstract: The hammerhead ribozyme according to the present invention produces a hammerhead ribozyme—target RNA construct by base-pairing with an edited target RNA, and an editing recognition site of the hammerhead ribozyme cleaves the modification site by forming a base pair with the target RNA modification site. The cleavage of the modification site is expected to be applicable to the research and development of new drugs that can be used to prevent or treat diseases caused by the edited target RNA.
    Type: Application
    Filed: May 19, 2012
    Publication date: August 14, 2014
    Applicant: Fukuoka University
    Inventors: Masatora Fukuda, Masanobu Deshimaru, Kei Kurihara